- Home
- AARD vs CHPT Comparison
AARD vs CHPT Comparison
Compare AARD & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | CHPT |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 155.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | AARD | CHPT |
|---|---|---|
| Price | $5.07 | $5.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 12 |
| Target Price | ★ $19.63 | $12.18 |
| AVG Volume (30 Days) | 375.2K | ★ 388.8K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $417,083,000.00 |
| Revenue This Year | N/A | $8.53 |
| Revenue Next Year | N/A | $11.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.74 | $0.51 |
| 52 Week High | $17.94 | $12.62 |
Technical Indicators
Market Signals| Indicator | AARD | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 22.62 | 32.76 |
| Support Level | $4.74 | $0.62 |
| Resistance Level | $15.88 | $6.73 |
| Average True Range (ATR) | 0.54 | 0.32 |
| MACD | -0.33 | -0.08 |
| Stochastic Oscillator | 4.23 | 3.04 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.